2018
Detection of heterozygous mutation in hook microtubule-tethering protein 1 in three patients with decapitated and decaudated spermatozoa syndrome
Chen H, Zhu Y, Zhu Z, Zhi E, Lu K, Wang X, Liu F, Li Z, Xia W. Detection of heterozygous mutation in hook microtubule-tethering protein 1 in three patients with decapitated and decaudated spermatozoa syndrome. Journal Of Medical Genetics 2018, 55: 150. PMID: 29330334, DOI: 10.1136/jmedgenet-2016-104404.Peer-Reviewed Original ResearchConceptsAssisted reproduction treatmentFertilization rateClinical studiesReproduction treatmentWhole genomic DNAPatientsTeratozoospermia patientsControl individualsNovel missense mutationAbnormal junctionProtein 1 geneHeterozygous mutationsIntramanchette transportUnreported mutationsHeadless tailsGenetic cuesPopulation-matched control individualsReduced fertilization ratesGenomic therapyMorphological observationsProtein 1Genomic DNADysfunctional proteinsFurther studiesMolecular mechanisms
2007
Variants in circadian genes and prostate cancer risk: a population-based study in China
Chu LW, Zhu Y, Yu K, Zheng T, Yu H, Zhang Y, Sesterhenn I, Chokkalingam AP, Danforth KN, Shen MC, Stanczyk FZ, Gao YT, Hsing AW. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer And Prostatic Diseases 2007, 11: 342-348. PMID: 17984998, DOI: 10.1038/sj.pcan.4501024.Peer-Reviewed Original ResearchConceptsProstate cancer riskLess insulin resistanceInsulin resistanceCancer riskGG genotypePopulation-based case-control studyGreater insulin resistancePopulation-based studyCase-control studyVariant C alleleCircadian genesProstate tumorigenesisC alleleNeed of confirmationMenRiskGenotypesVariantsGenes
2006
E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer
Lin J, Dinney C, Grossman H, Jhamb M, Zhu Y, Spitz, Wu X. E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer. Clinical Genetics 2006, 70: 240-245. PMID: 16922727, DOI: 10.1111/j.1399-0004.2006.00666.x.Peer-Reviewed Original ResearchConceptsSuperficial bladder cancerBladder cancer recurrenceBladder cancerCancer recurrencePromoter polymorphismHazard ratioCaucasian patientsMedian recurrence-free survivalMedical chart reviewRecurrence-free survivalRisk of recurrencePeripheral blood lymphocytesProportional hazards modelHomozygous CC genotypeChart reviewDisease recurrenceSmoking statusTumor recurrenceTumor stageBlood lymphocytesClinical dataCC genotypeHazards modelPatientsRecurrence riskDoes “Clock” Matter in Prostate Cancer?
Zhu Y, Zheng T, Stevens RG, Zhang Y, Boyle P. Does “Clock” Matter in Prostate Cancer? Cancer Epidemiology Biomarkers & Prevention 2006, 15: 3-5. PMID: 16434577, PMCID: PMC2366206, DOI: 10.1158/1055-9965.epi-05-0631.Peer-Reviewed Original ResearchConceptsProstate cancerSex hormone levelsFemale breast cancerCommon cancer typesEvening shift workHormone levelsPrognostic biomarkerBreast cancerAndrogen expressionProstate tumorigenesisCancerCancer typesShift workDaily biochemicalIndividual riskEtiologyCircadian rhythmGenetic variantsRiskCircadian clockCircadian cycleBiomarkersPhysiologicProfound effect
2005
Occupation and Risk of Pancreatic Cancer: A Population-Based Case–Control Study in Iowa
Zhang Y, Cantor KP, Lynch CF, Zhu Y, Zheng T. Occupation and Risk of Pancreatic Cancer: A Population-Based Case–Control Study in Iowa. Journal Of Occupational And Environmental Medicine 2005, 47: 392-398. PMID: 15824631, DOI: 10.1097/01.jom.0000158707.88801.f5.Peer-Reviewed Original ResearchNucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer
Gu J, Zhao H, Dinney C, Zhu Y, Leibovici D, Bermejo C, Grossman H, Wu X. Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer. Clinical Cancer Research 2005, 11: 1408-1415. PMID: 15746040, DOI: 10.1158/1078-0432.ccr-04-1101.Peer-Reviewed Original ResearchMeSH KeywordsAgedAllelesBCG VaccineDisease ProgressionDNA HelicasesDNA RepairDNA Repair EnzymesDNA-Binding ProteinsFemaleFollow-Up StudiesGene FrequencyGenotypeHumansMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalPoly-ADP-Ribose Binding ProteinsPolymorphism, GeneticSurvival AnalysisTime FactorsUrinary Bladder NeoplasmsXeroderma Pigmentosum Group A ProteinConceptsBacillus Calmette-Guerin treatmentRecurrence-free survival timeSuperficial bladder cancerShorter recurrence-free survival timeHigh recurrence riskDNA repair capacityHigh-risk allelesRecurrence riskPutative high-risk alleleVariant allelesClinical outcomesBladder cancerSurvival timeIntravesical bacillus Calmette-Guerin treatmentGene polymorphismsSuperficial bladder cancer recurrenceRepair capacityNucleotide excision repair gene polymorphismsRisk allelesCancer treatmentBladder cancer outcomesBladder cancer recurrenceBladder cancer treatmentMore risk allelesEnd of observation
2004
Methyl‐CpG‐binding domain 2
Zhu Y, Spitz M, Zhang H, Grossman H, Frazier M, Wu X. Methyl‐CpG‐binding domain 2. Cancer 2004, 100: 1853-1858. PMID: 15112265, DOI: 10.1002/cncr.20199.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceCase-Control StudiesDNA MethylationDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansLogistic ModelsMaleMolecular Sequence DataOdds RatioProbabilityPrognosisPromoter Regions, GeneticReference ValuesReverse Transcriptase Polymerase Chain ReactionRisk FactorsRNA, MessengerSensitivity and SpecificityUrinary Bladder NeoplasmsConceptsMBD2 expressionCarcinoma riskCurrent case-control studyReverse transcription polymerase chain reaction assaysCase-control studyPeripheral blood lymphocytesQuantitative reverse transcription-polymerase chain reaction assaysTranscription-polymerase chain reaction assaysMessenger RNA expressionReal-time quantitative reverse transcription-polymerase chain reaction assaysControl patientsLight smokersCase patientsHeavy smokersUnderlying molecular mechanismsTumor tissue typesBlood lymphocytesChain reaction assaysProtective effectProtective roleQuartile distributionDomain 2 proteinOlder individualsTumor developmentYoung individuals
2003
Telomere Dysfunction: A Potential Cancer Predisposition Factor
Wu X, Amos C, Zhu Y, Zhao H, Grossman B, Shay J, Luo S, Hong W, Spitz M. Telomere Dysfunction: A Potential Cancer Predisposition Factor. Journal Of The National Cancer Institute 2003, 95: 1211-1218. PMID: 12928346, DOI: 10.1093/jnci/djg011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlotting, SouthernCarcinoma, Renal CellCase-Control StudiesDNA DamageDNA RepairDNA, NeoplasmFemaleFlow CytometryGenetic Predisposition to DiseaseHead and Neck NeoplasmsHumansIn Situ Hybridization, FluorescenceKidney NeoplasmsLung NeoplasmsLymphocytesMaleMiddle AgedNeoplasmsOdds RatioRisk AssessmentRisk FactorsSmokingTelomereUrinary Bladder NeoplasmsConceptsControl subjectsTelomere lengthNeck cancerOdds ratioCancer riskShort telomeresOngoing case-control studyPercent of patientsRenal cell cancerCase-control studyPeripheral blood lymphocytesLongest quartileCase patientsCell cancerSmoking statusDisease characteristicsBladder cancerBlood lymphocytesStratified analysisGenetic instabilityHuman bladderRenal cellsStudy participantsCancerPredisposition factorsFrom genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity
Wang Y, Spitz M, Zhu Y, Dong Q, Shete S, Wu X. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair 2003, 2: 901-908. PMID: 12893086, DOI: 10.1016/s1568-7864(03)00085-5.Peer-Reviewed Original Research
2002
A case‐control analysis of lymphocytic chromosome 9 aberrations in lung cancer
Zhu Y, Spitz M, Strom S, Tomlinson G, Amos C, Minna J, Wu X. A case‐control analysis of lymphocytic chromosome 9 aberrations in lung cancer. International Journal Of Cancer 2002, 102: 536-540. PMID: 12432559, DOI: 10.1002/ijc.10762.Peer-Reviewed Original ResearchConceptsPeripheral blood lymphocytesChromosome 9 aberrationsLung cancerOdds ratioFamily historyPrimary lung tumorsLung cancer casesElevated odds ratiosCase-control analysisLung carcinoma specimensLung cancer predispositionFamily history analysisFrequent genetic changesEpidemiologic profileBlood lymphocytesLung tumorigenesisLung tumorsCancer casesCarcinoma specimensChromosome 9 abnormalitiesControl individualsCancerCytogenetic aberrationsFamilial aggregationChromosomal alterationsBPDE‐induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk
Zhu Y, Spitz M, Zheng Y, Hong W, Wu X. BPDE‐induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk. Cancer 2002, 95: 563-568. PMID: 12209748, DOI: 10.1002/cncr.10689.Peer-Reviewed Original ResearchMeSH Keywords7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxideAgedCarcinogensCarcinoma, Squamous CellChromosome AberrationsChromosomes, Human, Pair 3FemaleGenetic Predisposition to DiseaseGenetic TestingHead and Neck NeoplasmsHumansIn Situ Hybridization, FluorescenceLymphocytesMaleMiddle AgedPredictive Value of TestsConceptsPeripheral blood lymphocytesIndividual genetic susceptibilityGenetic susceptibilityTobacco carcinogensNeck squamous cell carcinomaNeck carcinoma riskSquamous cell carcinomaChromosomal aberrationsTobacco smoke constituentsDose-response relationshipTobacco exposureSpecific molecular targetsCell carcinomaHNSCC riskBlood lymphocytesRisk factorsOdds ratioCarcinoma riskPBL culturesCutoff pointLymphocytic cellsHNSCCBPDE sensitivityMolecular targetsSmoke constituentsGenetic instability of specific chromosomes associated with a family history of cancer
Zhu Y, Spitz M, Hsu T, Wu X. Genetic instability of specific chromosomes associated with a family history of cancer. Cancer Genetics 2002, 136: 73-77. PMID: 12165456, DOI: 10.1016/s0165-4608(02)00513-7.Peer-Reviewed Original Research
2001
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility.
Zhu Y, Spitz M, Lei L, Mills G, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Research 2001, 61: 7825-9. PMID: 11691799.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsLung cancer riskNucleotide polymorphismsLung cancer susceptibilityCancer susceptibilityG genotypeCancer riskLung cancerMatrix metalloproteinase-1 promoterTranscriptional activityGene expressionPromoter regionCurrent smokersCellular invasionCellular microenvironmentOncogenic mutationsMMP-1 promoter polymorphismTumor initiationTumor formationCancer developmentFrequency-matched controlsMMP-1 genotypesCase-control studyLung cancer casesMolecular epidemiological evidence